• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Mulpleta (lusutrombopag)

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Mulpleta (lusutrombopag)

  • Profile

Profile

Contact Information

Currently Enrolling Trials

    Show More

    General Information

    Mulpleta (lusutrombopag) is a small molecule thrombopoietin (TPO) receptor agonist.

    Mulpleta is specifically indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure.

    Mulpleta is supplied as a tablet for oral administration. The recommended dose is one 3-mg tablet taken once daily with or without food for 7 days. Begin Mulpleta dosing 8 to 14 days prior to the scheduled procedure. Patients should undergo their procedure 2 to 8 days after their last dose of Mulpleta. A platelet count prior to initiation of Mulpleta therapy should be taken and should not be more than 2 days before the procedure. Mulpleta should not be administered to patients with chronic liver disease in an attempt to normalize platelet counts.

    Clinical Results

    FDA Approval

    The FDA approval of Mulpleta was based on two randomized, double-blind, placebo-controlled trials (L-PLUS 1, L-PLUS 2).

    L-PLUS 1:

    A total of 97 patients with CLD—as defined by platelet counts <50,000 mcL—who were to undergo invasive procedure were randomized to receive 3 mg lusutrombopag or placebo. The primary endpoint of this trial was the proportion of patients who required no platelet transfusion prior to the primary invasive procedure. A significantly greater proportion of patients treated with Mulpleta did not require platelet transfusion versus placebo (78% versus 13%, respectively).

    L-PLUS 2:

    A total of 215 patients were randomized 1:1 to receive 3mg of lusutrombopag or placebo for up to seven days. Therapy was initiated on Day 1 and invasive procedures were performed between day nine and day 14. A pre-procedure platelet transfusion was mandated by the study protocol if a patient’s platelet count prior to the invasive procedure had not reached 50,000/µL. Lusutrombopag met the primary endpoint, which was defined as the proportion of patients who required no platelet transfusion prior to the procedure and no rescue therapy for bleeding through seven days following the procedure (64.8% of lusutrombopag patients versus 29% of placebo patients).

    Side Effects

    The most common adverse effect associated with the use of Mulpleta is headache.

    Mechanism of Action

    Mulpleta (lusutrombopag) is a small molecule thrombopoietin (TPO) receptor agonist. Lusutrombopag is an orally bioavailable, small molecule TPO receptor agonist that interacts with the transmembrane domain of human TPO receptors expressed on megakaryocytes to induce the proliferation and differentiation of megakaryocytic progenitor cells from hematopoietic stem cells and megakaryocyte maturation.

    Additional Information

    For additional information regarding Mulpleta or thrombocytopenia in adults with chronic liver disease scheduled to undergo a procedure, please visit https://mulpleta.com/

    Approval Date: 2018-07-01
    Company Name: Shionogi
    Back to Listings

    Upcoming Events

    • 26Jan

      Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

    • 27Jan

      Medical Device Clinical Trials in China: Latest Regulatory Developments

    • 11Feb

      Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era

    • 23Mar

      Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

    • 26Apr

      MAGI's Clinical Research vConference — Spring 2021

    Featured Products

    • Regenerative Medicine – Steps to Accelerate Development : PDF

      Regenerative Medicine: Steps to Accelerate Development

    • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

      Clinical Trial Agreements: A Guide to Key Words and Phrases

    Featured Stories

    • TechInnovation-360x240.png

      Pace of Technology Innovation in Trials Could Slow After Pandemic Eases

    • AskTheExperts-360x240.png

      Ask the Experts: Certifying and Maintaining Copies of Original Source Documents

    • Resources-360x240.png

      Trial Complexity, Endpoints Continue to Increase, Stretching Site Resources

    • FocusinRed-360x240.png

      Return to Focus on Risk Management Postpandemic Could Prove Challenging to Sites

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell My Personal Information

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing